SCHEMBL5735975

SCHEMBL5735975

CC(C)(C)c1ccc(-c2cccc(CO)n2)cc1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPV3 Q8NET8 11/20 0.51
KDR P35968 1/20 0.42
EPHB4 P54760 1/20 0.42
TEK Q02763 1/20 0.42
MPL P40238 1/20 0.40
ALDH1A1 P00352 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TNF P01375 1/20 0.40
NOD1 Q9Y239 1/20 0.40
KIF11 P52732 2/20 0.39
TRPV1 Q8NER1 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
ABL1 P00519 1/20 0.38
BCR P11274 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4592059 0.83 TRPV3 (0.61) TRPV3
SCHEMBL3625369 0.82 RAB9A (0.52) KDREPHB4TEKMPLALDH1A1
SCHEMBL27673847 0.79 MAPT (0.67) TRPV3ALDH1A1POLBMAPTHPGD
SCHEMBL2953474 0.78 MEN1 (0.60) TRPV3ALDH1A1POLBMAPTHPGD
SCHEMBL9009141 0.77 THRB (0.53) TRPV3ALDH1A1POLBMAPTHPGD
SCHEMBL30484292 0.77 THRB (0.53) TRPV3ALDH1A1POLBMAPTHPGD
SCHEMBL9009001 0.77 NOTUM (0.45) TRPV3ALDH1A1POLBMAPTHPGD
SCHEMBL27984694 0.77 RAB9A (0.64) KDREPHB4TEKMPLALDH1A1
SCHEMBL16675837 0.77 NPC1 (0.49) ALDH1A1POLBMAPTNPC1RAB9A
SCHEMBL805909 0.76 SCN9A (0.65) TRPV3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1244446-B1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2006-11-02 EP disclosed
US-6858630-B2 Naphthimidazole derivatives and their use as thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2005-02-22 US disclosed
US-20030083361-A1 Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia SMITHKLINE BEECHAM CORPORATION 2003-05-01 US disclosed
EP-1244446-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2003-01-08 EP disclosed
EP-1244446-A1 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2002-10-02 EP disclosed
WO-2001039773-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083361-A1 Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia MPL, THPO, TPO TRPV3 2610/4885KDR 219/4885EPHB4 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.